AcuityMD Raises $80M Series C at $955M Valuation to Expand AI Platform for MedTech Commercial Teams

Precision rarely announces itself. It just starts showing up in outcomes, in numbers that feel a little too sharp to be luck. AcuityMD just translated that kind of precision into $80M in Series C funding, landing at a $955M valuation that feels less like a finish line and more like a signal flare.

StepStone Group didn’t just lead this round, they reinforced a position, joined by Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. That is a table full of firms that don’t chase noise. They wait, they watch, then they move when the signal is too loud to ignore. This wasn’t optimism. This was recognition.

Michael Monovoukas read the gap early. MedTech has always been stacked with breakthrough products, but the commercial side has lagged behind, running on instinct where precision should live. AcuityMD steps into that void, connecting real world healthcare data with a platform that sharpens decision making down to who to target, where to focus, and when to move. Less guessing, more knowing. The kind of shift that compounds.

Robert Coe built the system to handle the chaos under the hood, turning fragmented data into something usable at speed. Lee Smith made sure it resonates where it counts, with the teams responsible for revenue, not just reporting. Together, they built something that doesn’t just inform. It directs.

The numbers tell their own story if you let them breathe. More than $160M raised to date. Nearly 500 MedTech companies on the platform. 8 of the top 10 already aligned. 16 of the top 20 now circling closer to action. And more than $34B in pipeline identified through the system. That is not surface level insight. That is embedded advantage.

The lesson here lands clean. This wasn’t about attaching buzzwords to a narrative. AcuityMD went deep into a single vertical, built infrastructure that actually maps how the market behaves, and tied it directly to revenue outcomes. They made data useful, then made it essential. That is how capital finds you, not the other way around.

For MedTech operators, the shift is already underway. Territory planning driven by instinct is losing ground to precision guided execution. The companies that understand where opportunity lives before the first call gets made are the ones pulling ahead while others recalibrate in real time.

AcuityMD is not just sharpening visibility. They are turning it into action, placing it directly in the hands of teams that close. That is how insight becomes revenue, and how quiet advantages turn into dominant positions.